COVID-19 vaccine and boosted immunity: nothing ad interim to do?

Página do item simplificado
dc.creatorRoncati, Luca
dc.creatorVadalà, Maria
dc.creatorCorazzari, Veronica
dc.creatorPalmieri, Beniamino
dc.date.accessioned2020-12-04T21:09:11Z
dc.date.available2020-12-04T21:09:11Z
dc.date.issued2020-11
dc.description.abstractToday, Coronavirus Disease 2019 (COVID-19) is a global public health emergency and vaccination measures to counter its diffusion are deemed necessary. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent of the disease, unleashes a T-helper 2 immune response in those patients requiring intensive care. Here, we illustrate the immunological mechanism to train the immune system towards a more effective and less symptomatic T-helper 1 immune response, to be exploited against SARS-CoV-2.pt_BR
dc.identifier.citationRONCATI, L. et al. COVID-19 vaccine and boosted immunity: nothing ad interim to do? Vaccine, [S.l.], v. 38, n. 48, p. 7581-7584, Nov. 2020.pt_BR
dc.identifier.urihttps://repositorio.ufla.br/handle/1/45766
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0264410X20313037pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsopenAccesspt_BR
dc.sourceVaccinept_BR
dc.subjectCOVID-19pt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectCorynebacterium parvum (C. parvum)pt_BR
dc.subjectBacillus Calmette-Guérin (BCG)pt_BR
dc.subjectHyaluronic acidpt_BR
dc.subjectCluster of differentiation 44 (CD44)pt_BR
dc.subjectVaccinept_BR
dc.titleCOVID-19 vaccine and boosted immunity: nothing ad interim to do?pt_BR
dc.typeArtigopt_BR

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
license.txt
Tamanho:
953 B
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)